Myologists working in Padua (Italy) were able to continue a half-century tradition of studies of skeletal muscles, that started with a research on fever, specifically if and how skeletal muscle contribute to it by burning bacterial toxin. Beside main publications in high-impact-factor journals by Padua myologists, I hope to convince readers (and myself) of the relevance of the editing
It is still unknown what the exact source and cause is of DNA mutations and deletions in vivo. Oxidative stress, in general, has been thought to be the major culprit, but what the original source of the culprit is, is still unknown. Iron dyshomeostasis (high cellular and low systemic levels) are strong risk factors in the development of disease, disability and premature death Systemic iron deficiency (anemia with old age) impairs oxygen carrying capacity, while in contrast increased cellular and mitochondrial levels may increase DNA lesions. Disturbances of iron metabolism including uptake, export, and storage have shown to play a causal role in cellular and mitochondrial dysfunctions with age and disease. Iron is found in several forms: heme iron (i.e., haemoglobin, myoglobin) and non-heme iron (i.e., Ferritin). A distinct fraction of chelatable non-heme iron is referred to as the labile iron pool, which comprises less than 5% of total cellular iron ( Figure 1 ). Labile iron consists of Fe2+ and Fe3+ ions associated with a variety of small molecules, including organic anions, polypeptides, and phospholipids. Labile iron can participate in Fenton reactions, producing highly destructive hydroxyl radicals, which are thought to be a major contributor to the formation of DNA mutatons and deletions. Cellular iron acquisition occurs through iron import proteins such as transferrin receptor (TfR1), divalent metal transporter-1 (DMT1), and Zip14, whereas cellular iron export is mediated by ferroportin (FPN), the only known iron exporter in mammals. The mitochondria contain mitoferrin (Mt iron importer), iron storage proteins such as frataxin, Mt ferritin (MtF) (which binds with iron), and ABCB7 (a heme export protein), all known to play an important role in the storage and regulation of Mt iron. We and others have found that in animals and humans, labile iron and nonheme iron increases with age and is associated with elevated expression of ferritin. In contrast, transferrin receptor 1 (TfR1; cellular iron import protein) showed a dramatic down regulation with age. We also find that mitochondrial iron levels effect Mt permeability transition pore opening susceptibility (i.e., Ca2+ retention capacity), mutations and deletions with age. We will present new data obtained from humans which show an association between iron deregulation and genome instability.
The ability to activate compensatory mechanisms in response to environmental stress is an important factor for survival and maintenance of cellular functions. A system that is often activated both in short and prolonged stress conditions is autophagy lysosome system (Milan et al, 2015) . 6 Autophagy is required to clear the cell from dysfunctional organelles and altered proteins and is reported to decline during ageing. This reduction causes accumulation of abnormal mitochondria and toxic proteins that contribute to precocious ageing sarcopenia (Carnio et al, 2014; Lapierre et al, 2015) . 7, 8 Here I'll present the last data about autophagy regulation, the role of autophagosomes in mitochondria turnover and the pathogenetic implications of deregulated autophagy in sarcopenia and in skeletal-to cardiac-muscle cross talk. Heart failure causes skeletal myopathy that affects both limb and respiratory muscles. The diaphragm is the primary respiratory muscle for inspiration, and in heart failure, abnormalities of the diaphragm occur earlier or to a greater extent than in limb muscles 9, 10 The diaphragm is the main 'pump' contributing to airway clearance (sneezing, coughing), adequate ventilation and gas exchange during physical activity, and reflex activation the sympathetic nervous system. 11, 12 Therefore, neuromuscular integrity of the diaphragm plays a critical role in the integrative pathophysiology of heart failure. The disease disrupts the dynamics of circulating factors (e.g. angiotensin II and cytokines) that trigger pathways involving sphingolipids, reactive oxygen species, and proteolysis leading to diaphragm neuromuscular junction alterations and intrinsic myocyte abnormalities (Fig. 2) . 13 Diaphragm myocyte abnormalities include decreased abundance of metabolic enzymes, oxidation of contractile and EC coupling proteins, fiber atrophy, loss of force, and accelerated fatigue. Our recent data show that effects of heart failure on the diaphragm depend on disease severity, involves a cross-talk between multiple Resistance training (RT) exerts many of its positive health effects through increase of strength and muscle mass. 15 Although these two variables are classically considered together (increase of muscle mass leads to an increase of strength, after the first period of neuromuscular adaptation) 16, 17 recently this assumption has been called into question. 18 Regardless their reciprocal influences both these adaptations (increase of muscle strength and cross sectional area, aka hypertrophy) are induced by RT but they could be of different magnitude in different individuals, thus one other critical issue in the field of RT's research is the existence of responders and nonresponders. In recent years this aspect was brought to attention by several studies, 19 e.g. Ahtiainen et al. demonstrated a great heterogeneity in muscle mass and strength responses to RT regardless sex and age, 20 whilst an earlier study showed high responders and low responders in term of muscle fiber CSA after a period of RT. 21 On the other hand recently Barbalho and colleagues analysing older women, 22 found that there are no nonresponders both to low or high volume RT. The question is intriguing and probably involves both individual/genetic specificity, 23 and the numerous variables of RT. 24, 25 In our opinion there is something that maybe best described as a "scotoma" in research on various training methodologies; if we don't consider the extremely wide range of different exercise execution we risk underestimating the importance and the effects of the different kinds of exercise. A resistance training program is a composite of several important variables including: 1) muscle action used, 2) type of resistance used, 3) volume (total number of sets and repetitions), 4) exercises selected and workout structure (e.g., the number of muscle groups trained), 5) the sequence of exercise performance, 6) rest intervals between sets, 7) repetition velocity and 8) training frequency. All these variables may influence muscle response to exercise and may be more effective in one individual compared to another. We recently demonstrated how the manipulation of rest intervals and number of reps could influence cellular signalling and long term muscle response (Figure 3 ]i using pharmacological agents and show that the ERG1a-induced increase is not sensitive to the L-type calcium channel blocker nifedipine, suggesting that it does not result from modulation of Cav1.1 channels; however, this increase is sensitive to the SERCA blocking agent thapsigargin, suggesting that the sources of the calcium are the sarcoplasmic reticulum stores. We have explored this further and preliminary data suggest that, relative to control transfected cells, ERG1a expressing myotubes may have a greater concentration of basal IP1, a metabolic product of IP3 which functions in the inositol signaling cascade by binding IP3 receptors to release calcium from the endoplasmic reticulum (Figure 4 ). In summary, to date the data show that ERG1a increases [Ca 2+ ]i levels and suggest that this increase could occur, at least in part, as a result of release of calcium from sarcoplasmic reticulum stores. Figure  4) . 32, 33 Importantly, we have recently documented that ER stress is heightened in dystrophic muscles from both human patients and mdx mice. 34 Further, in the same study, we demonstrated that ablation of Caspase-12, a mediator of the apoptotic response to ER stress ( Figure  5 ), improved functional capacity of muscles from adult mdx mice. To determine if this pathway was also contributing to pathology during periods of heightened transient ER stress, we examined the impact of caspase-12 ablation on muscles of mdx mice at the weaning transition, where there is exceptionally high ER stress, and also following acute injury in wildtype mice. Caspase-12 ablation reduced apoptosis and improved soleus function in 4 wk old mdx mice. Following cardiotoxin injection, there was a transient increase in ER stress markers in the regenerating limb muscles. With Caspase-12 ablation, the muscles tended to resolve damage more rapidly, with larger muscle fibers evident 11 days after cardiotoxin injection, and a 10% improvement is force generation. Taken together, blockade of the apoptotic arm of ER stress can ameliorate many aspects of dysfunction in both acute and chronic muscle injury. The NMJ is the specialized synapse which enables the communication between motor neurons and skeletal muscles. It is formed by the motor axon terminal (MAT) and the muscle fiber (MF), separated by a basal lamina, and by perisynaptic Schwann cells (PSC) that cover the MAT. An intense cross-talk takes place during NMJ maturation, and then a precise orchestration and a fine tuning of these signals maintain the synapse functional for a long time. 35, 36 NMJs are not protected by anatomical barriers, and are thus exposed to various damages, from traumas to poisons, bacterial and animal neurotoxins, or autoimmune antibodies. This lead to functional or physical denervation of MF and to neuroparalysis. For these reasons and for its essential role in life and survival, the NMJ has retained and refined throughout evolution the capacity to regenerate and remodel ( Figure 6 ). Depending on the nature of the insult, MAT can sprout new nerve terminals and form new synapses with the MF, or even re-form over degenerated MATs novel NMJs that look and perform as the original ones. Despite the wonder and the general importance of these properties, a molecular characterization is still lacking. 37 To fill this gap, we recently developed a novel experimental approach based on the use of neurotoxins to reversibly degenerate motor nerve terminals and to profile the signals exchanged among MAT, MF and PSC during regeneration 38, 39 by transcriptomics. We found that the chemokine CXCL12α, also known as stromal-derived factor-1 (SDF-1), is specifically produced by PSC following MAT degeneration and, together with its receptor CXCR4, is expressed by regenerating axon terminals, to orchestrate a molecular axis speeding up nerve terminal regeneration. Duchenne muscular dystrophy (DMD) is a caused by loss of the force transmitting and membrane complex organizing protein, dystrophin, and is characterized by progressive muscle deterioration with failed regeneration and replacement with a fatty-fibrous matrix. 40 A number of different targets for aspects of the disease have been identified, which potentially can be used in combination. However, the potential positive and negative interactions of these combinations must first be evaluated. One potential target is myostatin (MSTN) inhibition, which has been shown to increase muscle size and strength and decrease fibrosis in mouse and dog models of Duchenne muscular dystrophy. 41, 42 While human trials using myostatin inhibition in DMD patients are ongoing, there have been no published studies of the potential interactions between glucocorticoid steroids (current standard of care in DMD) and myostatin inhibitors, even though all patients in the current trials are receiving steroid treatments. To address this, we used a severe mouse model of DMD, the mdx mouse on the DBA background, which has heightened inflammation and fibrosis as compared to the more widely utilized mdx mouse on the C57/Bl10 background. To this severe mouse model, we administered either prednisolone alone (either 5mgs/kg once a day or once a week), MSTN inhibition alone (using AAV-driven secretion of the MSTN propeptide) 42 , or a combination of prednisolone and MSTN inhibition (Figure 7 ). In agreement with an earlier report, 43 we observed atrophy in the muscles of mdx mice treated with daily, but not weekly, steroids, and the expected hypertrophy from MSTN inhibition alone. However, the combination of daily steroids and MSTN inhibition either blunted or prevented (depending on the specific muscle) the MSTN-induced hypertrophy. These results suggest that the human DMD trials may not show the same MSTN benefits seen in animal models of DMD if the patients are on daily steroids. Facioscapulohumeral dystrophy (FSHD -MIM158900) is a frequent inherited myopathy, with a described prevalence ranging between 1:8000 and 1:20.000 (Deenen et al. 2014 ). 44 FSHD is clinically well characterized and in most cases can be readily distinguished from other myopathies because of the specific pattern of muscle involvement. In the past decade, major advances have been made in the understanding of the pathophysiological mechanism underlying this disease. FSHD is associated with epigenetic derepression in somatic cells of the highly polymorphic D4Z4 macrosatellite repeat located in the chromosome 4q subtelomere. In the most common form of FSHD, referred to as FSHD type 1 (FSHD1) derepression is caused by a contraction in the number of D4Z4 repeat units (RU) to a size of 1-10 RU. In the control population, the D4Z4 repeat varies between 8-100 RU. In the less frequent form, known as FSHD type 2 (FSHD2), derepression is associated with monoallelic mutations in genes encoding D4Z4 chromatin repressors, most often the structural maintenance of chromatin hinge domain containing 1 gene (SMCHD1; MIM# 614982) and rarely the DNA methyltransferase 3B gene (DNMT3B; MIM# 602900) 2012) . 45 In both FSHD1 and FSHD2 the presence of a non-canonical polyadenylation signal (PAS) distally to the derepressed D4Z4 repeat is mandatory to develop the disease. This PAS is only present only on 4qA subtelomeres (but not on 4qB subtelomeres, or chromosomes 10q which carry a highly homologous repeat in their subtelomere) and facilitates the skeletal muscle expression of the DUX4 retrogene of which a copy is located within each unit of the D4Z4 repeat array. DUX4 is a transcription factor normally expressed in the germline and cleavage stage embryos and its ectopic presence in muscle causes the inappropriate activation of a cascade of genes eventually leading to muscles cell death. SMCHD1 is a chromatin repressor acting in specific genomic regions: it is involved in X-chromosome inactivation, and the regulation of some gene clusters and mono-allelically expressed genes (Mason et al, 2017) . 46 Its exact function is unknown, but it likely plays a role in the maintenance of DNA methylation since its dysfunction invariably correlates with reduced DNA methylation at these loci. DNMT3B belongs to the family of DNA methyltransferases and is thought to be primarily (Figure 8 ). Phenotypic variability is found in both FSHD1 and FSHD2 and has been related to genetic and epigenetic modifiers of D4Z4 array methylation, 2012) 47 but also to other factors (hormones, age) (Teveroni et al; . 48 In addition to these modifiers, we will describe some atypical clinical phenotype of FSHD related to large deletion in SMCHD1 gene, (Renerd et al., in press) as well as new phenotype recently associated to mutations in SMCHD1 gene. We will address, the potential consequences of these findings in genetic counselling. 55 The term LGMD defines a progressive weakness with onset in the proximal limb girdle muscles, with age at onset of symptoms varying from early childhood (not congenital) to late adulthood. The progression of muscle weakness is usually symmetrical and variable among individuals and genetic type. The term LGMD used to molecularly classify the disease, becomes inappropriate for many patients when it is utilized to describe the clinical severity. Indeed, these disorders present a wide spectrum of muscle involvement and wasting, spanning from very severe forms, such as those with childhood onset and rapid progression, to relatively benign forms with late onset. The clinical phenotypes due to mutation in the LGMD genes include severe childhood-onset forms, distal and proximal myopathies, pseudo-metabolic myopathies, eosinophilic myositis, and hyperCKemia. Furthermore, patients with a clinically typical LGMD phenotype might carry mutations in the gene encoding emerin, which usually cause Emery-Dreifuss muscular dystrophy (EDMD) phenotype. Because there is a spectrum of phenotypes under the same genetic entity, and a wide genetic heterogeneity under the same phenotype, it is crucial to identify suitable selection criteria to be used when screening patients for the proteins and genes responsible for LGMD. Since LGMD is relatively rare in most populations, other more likely diagnoses need to be excluded. Dystrophinopathies (Duchenne dystrophy, Becker dystrophy, female carriers of Duchenne dystrophy) are the most relevant, and these diagnoses can be ruled out based on dystrophin protein testing and/or DNA mutation analysis in the dystrophin gene. BMD, which is characterized by an X-linked slowly progressive muscle weakness and often cardiac involvement, 56, 57 and is due to mutations in the dystrophin gene (X-linked). There are clinical cases of BMD that are oligosyntomatic and manifest only with cramps and myalgia. Muscle imaging (CT scan and MRI) may be helpful to characterize the severity and the pattern and distribution of muscle wasting ( Figure 9 ). The milder the symptoms are the more difficult is the diagnosis. In both LGMD and BMD our laboratory has evaluated the use of microRNA as biomarkers of disease evolution and correlated their elevation with pattern of muscle imaging. Specific patterns will be presented. Therapy is still an unresolved problem in LGMD and up to now limited to rehabilitation, clinical follow up with cardiologic and respiratory complications. In BMD the use of ACE inhibitors, steroid and cardiac transplantation is possible. 58 In skeletal myofibers, the large majority of the neuronal isoform of NO synthase (nNOS) localizes in the subsarcolemmal region, participating to the dystrophinglycoprotein complex (DGC). In muscle dystrophies, due to DGC disruption, but also in acquired neuromuscolar disorders, nNOS expression levels and subcellular distribution appear severely affected. The enzyme untethers from the sarcolemma and relocalizes in the sarcoplasm. In the absence of dystrophin, nNOS protein levels appear also severely reduced. Consequences of nNOS sarcoplasmic accumulation on muscle function vary, from no effect, to loss of force, and wasting. During muscle disuse/unloading, nNOS sarcoplasmic redistribution fosters nitrosative and oxidative stress, which exerts a further detrimental effect on myofiber atrophy, in concert with upregulation of "atrogenes", increased proteolysis, and arrest of protein synthesis. [59] [60] [61] Attenuated or absent muscle atrophy is observed by combining disuse/unloading either with nNOS knockout, or enzyme inhibition, or pharmacological treatments that preserve nNOS sarcolemmal localization ( Figure  10 ). [61] [62] [63] [64] Nevertheless, the actual role of nNOS subcellular redistribution in disuse muscle atrophy development remains still questionable, since the majority of studies investigated disused, atrophic muscles. Recent results obtained in collaboration with S. Gastadello (Karolinska Institutet, Stockholm) and concerning disused, nonatrophic muscles, from both humans and laboratory rats, indicate that nNOS dysregulation plays an initiating role in atrophy development. Before the onset of myofiber atrophy, the active enzyme redistributes from the subsarcolemma to the sarcoplasm, and transcript and protein levels display a significant, albeit transient, reduction. Furthermore, the early subcellular redistribution of active nNOS molecules occurs concomitantly with the increase of the translocation of the pro-"atrogene" transcription factor FoxO3 into myofiber nuclei. Additional evidence will be provided to demonstrate the requirement of active nNOS molecules to unloading-induced FoxO3 activation. ***** Single fiber proteomics in muscle plasticity and disease We have designed a mass spectrometry (MS)-based proteomic workflow that can extract large amounts of biological information from minute amounts of frozen muscle biopsies, laser-microdissected muscle fiber sections and freshly isolated single fibers. We first built a fixed resource consisting of deep human skeletal muscle proteomes which we used as libraries of identified peptide features. We then carried out singleshot MS analyses of laser-microdissected sections of single fibers and manually microdissected single fibers from human biopsies ( Figure 11 ). [65] [66] [67] Using the computational proteomics tool MaxQuant, we boosted protein identification in the patients' samples by matching their peptide features to the libraries. With our workflow, triplicate proteome analyses of few micrograms of tissue from one patient can be carried out with minimized hands-on and machine time, yielding quantitative and molecularly defined information. We have applied our proteomic platform to mitochondrial disorders, a particularly complex and heterogeneous group of disorders characterized by mutations in mitochondrial DNA (mtDNA) or in nuclear mitochondrial genes. This leads to a plethora of multisystemic disorders that may literally manifest with any symptom, in any organ, and at any age. Quantitative proteomics may help to bridge the gap between genotype and phenotype and to tackle unsolved questions in mitochondrial medicine. Using the combined cytochrome oxidase/succinate dehydrogenase (COX/SDH) staining, an important diagnostic signpost to indicate mitochondrial defects, we here use laser capture microdissection (LCM) to separate pools of COX+ and COX-muscle fibers from patients suffering from chronic progressive external ophthalmoplegia (CPEO), the disease in which this heterogeneity was initially identified. Our results reveal compensatory mechanisms for the energy deficit caused by mitochondrial defects and suggest novel causal relationships to disease in patients. Figure 12 ). The role of TNPO3 in muscle is unknown, but its involvement in nuclear import of protein, also involved in RNA splicing, leads to different hypothesis about how TNPO3 mutation can cause LGMD1F. [68] [69] [70] [71] [72] [73] For example, the mutation could block the whole activity of TNPO3 or make it unable to interact with its cargo proteins, causing the block of the nuclear import of a pattern of proteins involved in RNA splicing. Consequently, this would lead to altered synthesis of cytoskeletal and myofibrillar proteins probably causing disarray of the normal muscle fiber architecture. We have studied the expression of TNPO3 in murine and human myoblasts which, under appropriate culture conditions, differentiate into myocytes; myogenic differentiation was confirmed by the expression of specific differentiation markers (myogenic regulatory factors, desmin and myosin). We evaluated TNPO3 expression at different time points (early, middle and late) during myogenic differentiation and we observed a similar behaviour for both murine and human cells. In the early phase of cell differentiation TNPO3 expression increases and shows nuclear and cytoplasmic localization, while decreasing in the middle stage with a localization mainly limited to the cytoplasm. In the late differentiation step, TNPO3 goes back to increase and localize particularly in the cytoplasm. In addition we verified the pattern of expression of some myomiRNAs (miRNA 1, miRNA 206, miRNA 133) specifically involved in myogenesis and atrophy, which expression increases during differentiation. In the end we analyzed the expression of some specific proteins involved in muscle atrophy (such as Murf-1 and p62), which remains the common feature of myofibres of LGMD1F patients. Total Hip Arthroplasty is becoming a common, successful orthopedic procedure worldwide; however, to date there has been little emphasis on understanding the patient-specific recovery process post-surgery. [74] [75] [76] [77] [78] [79] Thus, we aim to determine a multi-metric assembly as a first step toward creating a clinical tool to assess patient recovery. Here, at both pre-and one-year post-surgery time points, we measured 11 spatial temporal gait parameters, bone mineral density around the implant stem, tissue density of and electro-myographic signals from the rectus femoris, vastus lateralis, and vastus medialis muscles. We completed computer tomographic scans on 48 total hip arthroplasty patients (receiving either cemented or uncemented implants) undergoing unilateral primary surgery. 75 To create the multi-metric assembly, we first determined which variables showed a significant difference between their pre-and postsurgery measurements for each patient using either Student t-tests or Wilcoxon signed rank tests, depending on variable distribution type. 78 We then used principal component analytic methods, 76, 77 to determine which variables, out of those demonstrating significant differences, contributed redundant information to the dataset. 77 Those variables were then removed from the original set of significant variables. For both analyses, we determined normalcy of the variables using ShapiroWilks tests and transformed those that were non-normal Table  2 ). The variables which were most sensitive to postoperative changes were the gait measurements, the muscle densities of the rectus femoris and vastus medialis, both the proximal and distal bone mineral densities, and one electromyographic signal. To summarize, using the principal component analysis, we determined a subgroup of 5 variables which decreased redundancy in the dataset. Our findings indicate that developing a tool to assess patient recovery post-surgery is clinically feasible. The stimulation parameters applied for eliciting muscle contractions are depending on physiological conditions of the muscle. Of particular importance for electrical stimulation is whether the connection between the muscle and the nerve is preserved or the muscle is denervated due to Spinal Cord Injury or peripheral nerve lesion. In the latter cases the denervated muscle becomes unexcitable with commercial electrical stimulators and undergoes ultra structural disorganization within a few months, while severe atrophy with nuclear clumping and fibro-fatty degeneration appears later on within 3 and 6 years. [80] [81] [82] This changes are essential for developing stimulation protocols since functional activation of denervated muscles requires electrical stimulation with long impulse duration in the range of 20 -150 (up to 300) ms. Moreover, contrary to innervated muscle where the nerve distributes the action potential in the denervated muscle an electrical field distribution capable of depolarizing the fibers in almost every part of the muscle has to be achieved. Therefore, to counteract the deterioration of the denervated muscle a therapy concept for home-based electrical stimulation was developed. To carry out the training a stimulator suited to deliver the necessary high-intensity and long duration impulses and new electrodes were designed. 83, 84 Specific clinical assessments to monitor the condition of the patient's muscles and guidelines for training were developed at the Wilhelminenspital Wien, Austria. 83 The novel therapy concept ( Figure 13 ), together with the newly designed devices, was evaluated in the RISE clinical study. After completing the 2-year home-based therapy program the subjects showed a significant increase of muscle mass and of myofiber size, improvements of the ultrastructural organization and recovery of tetanic contractility with significant increase in developed muscle force output during electrical stimulation. 84 
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Fig 10. Distribution of nNOS active molecules and myofiber size of unloaded rat soleus muscle. A) Unloading induces redistribution of active nNOS molecules (blue) from subsarcolemma to sarcoplasm and decreases myofiber cross-sectional area (CSA). B-C) No or mild reduction in myofiber CSA is induced by unloading in nNOS-KO mice (B) or after inhibition of nNOS using 7-nitroindazole (C); note that in C) unloading still induces sarcoplasmic redistribution of inactive nNOS molecules. D-F)Unloading does not affect sarcolemmal distribution of active nNOS molecules and mildly decreases myofiber CSA, after upregulation of Grp94 (light blue, D), an endoplasmic-reticulum chaperone which interacts with nNOS, or curcumin administration (E). Panel F demonstrates that curcumin administration does not counteract unloading-induced nNOS sarcoplasmic redistribution and myofiber atrophy, when Grp94 expression is downregulated by antisense cDNA (orange).
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